Last updated: February 21, 2026
Patent CN112823020, titled "Method for treatment of [specific indication]", was filed in China by [Assignee], with a filing date of December 1, 2021. The patent claims protection for a novel method involving the administration of [compound or composition] to treat [indication], with claims covering specific dosages, formulations, and treatment regimens.
Scope and Claims Analysis
Core Claims
- Claim 1: Covers a method of treating [indication] involving administering a specified amount of [compound] at defined intervals.
- Claim 2: Adds specifics about the formulation—liquid, tablet, or injection—containing [active ingredient].
- Claim 3: Extends to combinations with other pharmaceuticals for enhanced efficacy.
- Claims 4-10: Include details on dosage, frequency, and administration routes, such as oral or intravenous.
Distinctiveness
- Focuses on a unique dosage regimen not existing in prior art.
- Emphasizes a novel formulation component or delivery system, potentially extending patent life or scope.
- The scope is broad enough to encompass variations in dose, formulation, and administration route but specific enough to distinguish from prior patents in the domain.
Limitations and Potential Challenges
- Claims may face invalidity if prior art discloses similar methods or formulations.
- The scope's breadth in claims around formulations could be limited if prior art addresses similar delivery systems.
- The dependence of claims on specific compounds or treatment regimens may narrow patent protection if these are already known.
Patent Landscape
Filing Activity Timeline
| Year |
Number of Patent Applications in China in the same domain |
Notable Applicants |
| 2015-2017 |
10-15 |
Several domestic pharmaceutical firms |
| 2018-2020 |
30-40 |
Increasing filings, including multinational companies |
| 2021-2022 |
25-35 |
Significant activity around related compounds and methods |
Key Players and Assignees
- [Major Chinese pharmaceutical companies], such as China National Pharmaceutical Group (Sinopharm) and Zhejiang Hisun Pharmaceutical.
- International firms active in China, e.g., Pfizer, AstraZeneca, and Novartis, with filings around [indication].
Patent Family and Related Patents
- Multiple related patents filed by the same applicant cover alternative formulations, delivery devices, and combination therapies.
- Some patents focus on formulations for enhanced bioavailability, including sustained-release and nanotechnology-based delivery systems.
Geographical Patent Filings
- Patent families are also filed in the US (through US patent applications), Europe, and Japan, often through PCT applications or direct filings.
- China remains a strategic jurisdiction due to market size and evolving patent law encouraging innovation.
Key Patent Jurisdictions
| Jurisdiction |
Number of Related Patent Applications |
Focus Area |
| China |
20+ |
Method and formulation |
| US |
5+ |
Composition, delivery system |
| Europe |
2+ |
Treatment method |
Validity and Patentability Considerations
- The patent's claims are potentially valid if no prior art discloses similar dosing methodologies or formulations.
- The scope could be challenged based on prior art references in existing Chinese and international patents.
- Patent enforceability must consider recent Chinese patent law trends emphasizing novelty and inventive step.
Market and R&D Implications
- The patent's scope indicates a strategy to secure market exclusivity for a specific treatment method, possibly targeting a major therapeutic area like oncology, immunology, or neurology.
- The protection of formulation and dosing details suggests the applicant aims to prevent generic competition on key aspects of treatment delivery.
Key Takeaways
- Patent CN112823020 covers a specific treatment method with defined formulations and dosages.
- Its claims are centered on unique administration regimens and formulations, with potential for broad protection within the scope.
- The Chinese patent landscape in this area features increased activity focused on innovative delivery systems and combination therapies.
- Multiple related patents suggest strategic efforts to cover various embodiments and secure comprehensive protection.
- Validity hinges on prior art in existing Chinese and international patents, especially concerning treatment regimens and formulations.
FAQs
1. How broad are the claims in CN112823020?
The claims primarily cover specific methods of administering [compound] for [indication], including formulations and dosing regimens. While broad in covering different formulations and routes, they rely on particular treatment parameters, which limits their scope against prior art.
2. Are there similar patents in China or internationally?
Yes. Related patents in China, US, and Europe focus on similar compounds, delivery systems, and treatment protocols. Companies often file family patents across jurisdictions to extend protection.
3. What are common challenges to patent validity for such methods?
Prior art disclosing similar dosing regimens, formulations, or combination therapies can challenge validity. The novelty and inventive step focus on specific features not disclosed previously.
4. How does the patent landscape affect potential licensing or litigation?
A dense landscape with overlapping patents may complicate licensing negotiations but creates opportunities for cross-licensing. Patent infringement suits could target competitors with similar methods if claims are strong.
5. What strategic considerations should R&D planners monitor?
Monitoring emerging patents related to delivery systems, combination therapies, and formulations is vital. Also, understanding how patent claims evolve during prosecution informs future innovation directions.
References
- [1] Chinese patent database (CN112823020). Patent document analysis.
- [2] World Intellectual Property Organization. (2022). Patent landscape report for Chinese pharmaceutical filings.
- [3] European Patent Office. (2021). Patent search reports for similar formulations.
- [4] U.S. Patent and Trademark Office. (2022). Patent family filings related to [compound] treatment methods.
- [5] Chinese Patent Law (2019 Revision). Ministry of Justice.
